We searched PubMed and Scopus for English-language reports (2015–2025, plus earlier foundational studies) using combinations of glioma OR glioblastoma AND (NF-κB OR COX-2 OR PGE2 OR EP2 OR EP4 OR NLRP3 OR IL-1β) AND (polyphenols OR sulforaphane OR honokiol OR ginsenosides OR ω-3 OR specialized pro-resolving mediators OR berberine). This evidence concerns the gene PTGS2 and central nervous system cancer.